MedTrace Logo

Nimotuzumab in Adults With Glioblastoma Multiforma

NCT00753246 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2012-12-03

No results posted yet for this study

Summary

Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma

Conditions

  • Adults With Glioblastoma Multiforma

Interventions

DRUG

nimotuzumab

monoclonal antibody

Sponsors & Collaborators

  • Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany

    collaborator UNKNOWN

  • University of Bonn

    collaborator OTHER

  • Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • Johann Wolfgang Goethe University Hospital

    collaborator OTHER

  • University of Giessen

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • University of Kiel

    collaborator OTHER

  • Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany

    collaborator OTHER

  • Universität Tübingen

    collaborator OTHER

  • Oncoscience AG

    lead INDUSTRY

Principal Investigators

  • Manfred Westphal, Prof. MD · University Hamburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2012-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00753246 on ClinicalTrials.gov